Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions

Biochemical and Biophysical Research Communications
M F WalterR P Mason

Abstract

The biological activity of the Alzheimer's disease amyloid beta protein may be related to modulation of membrane lipid peroxidation. The effect of amyloid beta protein fragment 25-35 [A beta(25-35)] on lipid peroxidation was examined in liposomes enriched with polyunsaturated fatty acids. The activity of A beta(25-35) was compared to that of A beta(25-35) with either a scrambled sequence [A beta(25-35)scram] or a peptide sequence in which methionine was replaced with leucine [A beta(25-35) met]. A beta(25-35) inhibited lipid peroxidation in a dose- and time-dependent manner. The antioxidant activity of A beta(25-35) was observed at concentrations as low as 10 nM. The relative antioxidant activities of the amyloid beta protein fragments were as follows: A beta(25-35) > A beta(25-35) met > A beta(25-35)scram. The two more potent peptides intercalated into the membrane hydrocarbon core, as determined by small-angle x-ray diffraction approaches. These findings indicate that the amphiphilic A beta(25-35) peptide inhibits lipid peroxidation at low concentrations as a result of physicochemical interactions with the membrane lipid bilayer.

References

Mar 14, 1990·Neuroscience Letters·J S WhitsonC W Cotman
Feb 12, 1988·Cell·G G Glenner
Oct 13, 1995·The Journal of Biological Chemistry·C J PikeC W Cotman
Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·K HensleyD A Butterfield
Feb 1, 1993·The Biochemical Journal·S Gebicki, J M Gebicki
Jan 17, 1996·Annals of the New York Academy of Sciences·D J SelkoeC Haass
May 6, 1996·Biochemical and Biophysical Research Communications·R P MasonP E Mason
Jun 25, 1996·Proceedings of the National Academy of Sciences of the United States of America·J F KellyM P Mattson

❮ Previous
Next ❯

Citations

Oct 3, 1999·European Journal of Biochemistry·M Del Mar Martínez-SenacJ C Gómez-Fernández
Dec 9, 2000·American Journal of Respiratory and Critical Care Medicine·J G LaffeyB P Kavanagh
Apr 1, 2005·Proceedings of the National Academy of Sciences of the United States of America·Yechun XuHualiang Jiang
Apr 26, 2006·American Journal of Alzheimer's Disease and Other Dementias·Rudy J CastellaniMark A Smith
May 24, 2006·Acta Neuropathologica·Rudy J CastellaniMark A Smith
May 25, 2005·International Journal of Experimental Pathology·Hyoung-Gon LeeMark A Smith
Jun 5, 1998·The Journal of Biological Chemistry·S K RheeR Lal
Jun 2, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Y J ZhuR Lal
Dec 21, 2004·Brain Pathology·Anatol Kontush
Mar 13, 2015·Biomedit︠s︡inskai︠a︡ khimii︠a︡·E E DubininaD V Zakharchenko
Aug 6, 2000·Biochemical Pharmacology·R P MasonR F Jacob
Dec 26, 2009·Neurobiology of Disease·Akihiko NunomuraGeorge Perry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.